Ultragenyx Pharmaceutical Inc. (RARE) Shareholders’ equity 2016–2025
Ultragenyx Pharmaceutical Inc. (RARE) shareholders’ equity at each fiscal year-end, per SEC filings.
-$80.0MFY2025 · since FY2016: $474.0M → -$80.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$80.0M | -131.4% |
| FY2024 | $255.0M | -7.3% |
| FY2023 | $275.0M | -21.9% |
| FY2022 | $352.0M | -61.8% |
| FY2021 | $922.6M | -20.1% |
| FY2020 | $1.2B | +76.6% |
| FY2019 | $653.8M | +7.4% |
| FY2018 | $608.9M | +58.8% |
| FY2017 | $383.5M | -19.1% |
| FY2016 | $474.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice